Bill MacLeod is serving as the ABA Section of Antitrust Law’s 2016-2017 Chair. Below is his most recent message as posted on the ABA website:

Competition, Disruption and Transition: The Future of Enforcement at Fall Forum

Nobody I know in the competition or consumer protection bar can remember when more investigations, more complaints, and more

On October 12, 2015, the Antitrust Bureau of New York Attorney General’s Office sent a letter of inquiry to Turing Pharmaceuticals asking about its 5000 percent increase in the price of its recently acquired AIDS drug Daraprim.  Among other things, the letter suggests Turing is limiting distribution of the drug only through a small number

Last April, Monsanto Co. offered to buy Syngenta AG for USD 44.3 billion.  Syngenta rejected the offer claiming that Monsanto undervalued the company and underestimated the potential antitrust risk.  On June 25, four law firms, including Arnold & Porter, Cadwalader, Paul Hastings and Wilmer Hale, “sided” with Monsanto stating the acquisition would pose

In an editorial published by the Baltimore Sun on May 15, 2015, Robert Reich lamented the “appalling weakness” of modern antitrust.  His opinion was written mostly in reaction to what he viewed as the tepid response of the Antitrust Division to alleged price fixing in the currency exchange markets.  His broader point was that the